160
Participants
Start Date
March 30, 2022
Primary Completion Date
May 31, 2027
Study Completion Date
June 30, 2028
Placebo
During the extended dosing of abatacept, those randomized to receive 4 doses will receive a placebo consisting of an equal volume of normal saline solution.
Abatacept
Investigational prophylaxis with extended-dosing abatacept, a calcineurin inhibitor and methotrexate.
University of Rochester, Rochester
Children's Hospital of Philadelphia, Philadelphia
Emory University/Winship Cancer Center, Atlanta
Moffitt Cancer Center, Tampa
Cincinnati Children's Hospital, Cincinnati
University of Michigan, Ann Arbor
University of Chicago, Chicago
Washington University St. Louis, St Louis
City Of Hope National Medical Center, Duarte
Oregon Health and Sciences University, Portland
Massachusetts General Hospital, Boston
Boston Children's Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Boston Children's Hospital
OTHER